News

Polykon Manufacturing LLC merges with Seppic Inc. and becomes Seppic Inc. Richmond

Since its opening in 2020 in Richmond, Virginia, the Polykon Manufacturing LLC facility has strengthened Seppic’s proximity to our North American customers and expanded our manufacturing capabilities. Effective January 1, 2024, Polykon Manufacturing LLC took the next step by merging with its parent company, Seppic Inc.

This change brings consistency to the organization of Seppic’s manufacturing facilities and supports the company’s strategy to deliver a simplified customer experience. Seppic continues to grow by addressing multiple markets around the world, always with the highest level of service, while strengthening its brand image in the United States.

Seppic Inc. Richmond produces in particular SEPIMAX ZEN™, SEPINOV™ EMT 10, SEPINOV™ WEO, SIMULGEL™ NS, or SIMULGEL INS 100™. As a major global player in rheology modifiers, the Seppic Group continually invests in its production facilities in the United States to provide a high level of service to its customers.

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business